Healthcare company Grail has revealed plans to examine a next-generation sequencing (NGS) technology-based blood test for the early detection of various cancer types in the new SUMMIT study.

Set to begin early next year, the prospective, observational, longitudinal, cohort study will recruit nearly 50,000 men and women aged between the ages of 50 and 77 years old and who are undiagnosed at the time of enrolment.

Around 50% of the participants to be involved in the study will be those who are at high risk for lung and other cancers due to a significant smoking history. The remaining 50% will be people who are not at high risk for cancer based on smoking history.

“The objective of the study is to assess the ability of the NGS blood test to detect cancer.”

SUMMIT will be carried out in the UK in alliance with University College London (UCL) and University College London Hospitals National Health Service (NHS) Foundation Trust (UCLH).

The objective of the study is to assess the ability of the NGS blood test to detect cancer.

Grail Clinical Development vice-president Anne-Renee Hartman said: “The SUMMIT study will support the development of our blood test for the early detection of multiple cancer types in a diverse population.

“We are excited to partner with UCL, University College London Hospitals NHS Foundation Trust, and Lung Cancer Alliance on the SUMMIT study, as we continue to evaluate new ways to improve the early detection of cancer.”

Study participants will gain access to lung cancer screening with low dose computed tomography (LDCT) and resources for smoking cessation through the UK National Health Service (NHS).

In addition to SUMMIT, the GRAIL clinical research programme includes two separate studies, CCGA and STRIVE, evaluating the NGS blood test for cancer detection.